Wake Forest Atrium HeartShare Clinical Center

维克森林中庭 HeartShare 临床中心

• 批准号: 10678972
• 负责人: DALANE W KITZMAN
• 金额: $ 27.47万
• 依托单位: WAKE FOREST UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-10 至 2026-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10678972
• 关键词: Abdomen; Acceleration; Address; Adipose tissue; Age; Aging; Aorta; Artificial Intelligence; Biological; Biological Markers; Biopsy; Blood; Blood Vessels; Body Composition; Brain; Cardiac; Clinical; Cognition; Collaborations; Complement; Consensus; Consent; Control Groups; Creativeness; DNA; Data; Development; Diabetes Mellitus; EFRAC; Educational workshop; Electrocardiogram; Electronic Health Record; Enrollment; Ensure; Evidence based treatment; Functional disorder; Funding; Future; Genetic Materials; Goals; Health; Health system; Heart; Heart Atrium; Heart failure; Heterogeneity; Hypertension; Image; Institution; International; Intervention; Lead; Leadership; Lung; Machine Learning; Magnetic Resonance Imaging; Mental Depression; Mitochondria; Monitor; Morbidity - disease rate; Muscle; Obesity; Outcome; Paper; Participant; Pathogenesis; Patient Recruitments; Patients; Phase; Phenotype; Physical activity; Plasma; Population Heterogeneity; Population Study; Prevalence; Prognosis; Protocols documentation; Qualifying; Quality of life; Recommendation; Reporting; Research Personnel; Research Priority; Resources; Sampling; Seminal; Serum; Signal Transduction; Skeletal Muscle; Specimen; Structure; Syndrome; Techniques; Testing; Thigh structure; Tissue Sample; United States National Institutes of Health; Visit; Work; actigraphy; bioinformatics tool; cardiac magnetic resonance imaging; career; clinical center; cohort; comorbidity; data repository; deep learning; design; experience; forest; frailty; gender diversity; innovation; insight; microbiome; mortality; multidisciplinary; new therapeutic target; novel; preservation; primary outcome; programs; prospective; racial diversity; randomized trial; recruit; response; retention rate; signal processing; success; therapeutic target

Project Summary Heart Failure with Preserved Ejection Fraction (HFpEF) is the most common form of HF in the US and is associated with high morbidity and mortality. However, its pathophysiology is incompletely understood, and most trials have been neutral such that few evidence-based treatments exist. In response, NIH convened 2 workshops co-led by Dr. Kitzman (PI). The highest priority research recommendation was a coordinated effort to create a large cohort of HFpEF patients and controls and perform comprehensive, deep phenotyping. This became the basis for HeartShare, whose ultimate goals are to discover novel HFpEF mechanisms, subtypes, and therapeutic targets. Our Wake Forest - Atrium HFpEF team is highly qualified to serve as a Clinical Center and make robust, over-arching contributions to HeartShare. Dr. Kitzman is internationally recognized as a thought-leader in HFpEF with a sustained track record of developing novel concepts regarding HFpEF pathogenesis, mechanisms, and outcomes and designing and conducting innovative studies to test them. His team has extensive experience in all key aspects of the HeartShare program, particularly in recruiting, retaining, and phenotyping diverse populations of HFpEF patients and controls, often significantly exceeding goals for racial and gender diversity. Our institutions have ~15,000 HFpEF clinical visits annually. In all, our team has led or helped lead recruitment and phenotyping for 69 studies, mostly NIH-sponsored, with 15,354 participants, demonstrating our ability to fulfill HeartShare recruitment and phenotyping goals. Data from these studies will be contributed to the Cohort phase of HeartShare. We will make robust contributions to HeartShare by achieving 4 Specific Aims: Aim 1) Provide ‘thought leadership’ in collaboration with the HeartShare Steering Committee; Aim 2) Contribute data, images, and stored specimens cohort phase of HeartShare from our numerous studies of HFpEF and controls, and identify and phenotype HFpEF patients and controls from the electronic health record using robust bioinformatics tools; Aim 3) Recruit, consent, enroll and follow at least 250 HFpEF patients plus controls (type and number to be determined by consensus); Aim 4) Conduct state-of- the-art deep phenotyping exams using a collaboratively determined protocol. Our phenotyping proposal is highly innovative, with advanced echo-Doppler and cardiac magnetic resonance imaging, CPET, physical activity monitoring, remote and artificial intelligence electrocardiography, sampling of skeletal muscle, adipose, blood, and microbiome, and mitochondrial energetics, and brain structure/function. Our diverse, cross- disciplinary team has the full range of complementary expertise and access to the robust resources of two large, closely affiliated health systems to ensure fulfillment of all HeartShare’s goals. We will help accelerate and optimize the program’s success with our insight, creativity, and sustained track record of collaboration, innovation, and dissemination.

项目摘要 保留的射血分数（HFPEF）的心力衰竭是美国最常见的HF形式，是 与高发病和死亡率有关。但是，其病理生理学尚不完全理解，并且 大多数试验都是中性的，因此很少有基于证据的治疗。作为回应，NIH召集了2 Kitzman博士（PI）共同领导的研讨会。最高优先研究建议是协调的努力 创建大量的HFPEF患者和对照组，并进行全面的深层表型。这 成为心灵的基础，其最终目标是发现新颖的HFPEF机制，亚型， 和治疗靶标。我们的Wake Forest -Atrium HFPEF团队非常有资格担任临床中心 并为心脏展示做出强大的统治贡献。基兹曼博士在国际上被公认为 HFPEF中的思想领导者具有开发有关HFPEF的新颖概念的持续记录 发病机理，机制，结果以及设计和进行创新研究以测试它们。他的 团队在心脏展览计划的所有关键方面都有丰富的经验，尤其是在招募， 保留HFPEF患者和对照组的潜水员种群，并表现出表型，通常显着超过 种族和性别多样性的目标。我们的机构每年进行约15,000个HFPEF临床访问。总的来说，我们的 团队领导或帮助领导招聘和表型进行69项研究，其中大部分是由NIH赞助的，其中15,354 参与者展示了我们实现心脏招募和表型目标的能力。这些数据 研究将有助于心脏病的队列阶段。我们将为心脏做出强大的贡献 通过实现4个特定目标：目标1）与心脏榜样合作提供“思想领导” 委员会;目标2）从我们的 大量研究HFPEF和对照，并识别和表型HFPEF患者以及对照 使用强大的生物信息学工具的电子健康记录；目标3）至少招募，同意，注册和关注 250名HFPEF患者加对照组（由共识确定的类型和数字）；目标4） 使用协作确定的协议进行的深层表型考试。我们的表型建议是 高度创新，具有高级回声多普勒和心脏磁共振成像，CPET，物理 活动监测，远程和人工智能心电图，骨骼肌的取样，脂肪， 血液和微生物组以及线粒体能量以及大脑结构/功能。我们的潜水员，交叉 纪律团队拥有各种完整的完整专业知识，并获得了两个的强大资源 大型，密切相关的卫生系统，以确保实现所有心脏的目标。我们将帮助加速 并通过我们的洞察力，创造力和持续的协作记录来优化该计划的成功， 创新和传播。